Yes, large B-cell lymphoma is a type of non-Hodgkin lymphoma (NHL). More specifically, diffuse large B-cell lymphoma (DLBCL) is the single most common subtype, accounting for 25% to 30% of all non-Hodgkin lymphoma cases worldwide. It develops when large, mature white blood cells called B-lymphocytes begin growing out of control, most often in the lymph nodes but sometimes in organs outside the lymphatic system.
Where DLBCL Fits in the Lymphoma Family
All lymphomas fall into one of two broad categories: Hodgkin lymphoma and non-Hodgkin lymphoma. The key biological difference is the type of abnormal cell involved. Hodgkin lymphoma contains a specific large cell called a Reed-Sternberg cell, while non-Hodgkin lymphomas do not. More than 30 subtypes of NHL have been identified, and DLBCL is the most common, followed by follicular lymphoma.
DLBCL is classified as an aggressive (fast-growing) lymphoma. That sounds alarming, but it also means the cancer cells are actively dividing, which makes them more responsive to treatment than some slower-growing types. About 60% of cases are found in the lymph nodes, while 40% appear in extranodal sites like the stomach, brain, bone, or skin.
What Happens in the Body
In a healthy immune system, B-cells mature in the bone marrow and then move into lymph tissue, where they help fight infections by producing antibodies. During this maturation process, B-cells undergo complex genetic rearrangements that can occasionally go wrong. In DLBCL, these errors lead to the activation of genes that promote cell growth (oncogenes) and the silencing of genes that normally stop damaged cells from multiplying (tumor suppressors).
One particularly important change involves a gene called BCL2, which produces a protein that prevents cells from dying on schedule. When BCL2 is overexpressed, which happens in 15% to 30% of DLBCL cases, the abnormal B-cells accumulate instead of being cleared away. This progressive buildup of a single clone of malignant lymphocytes is what forms the tumor.
Common Symptoms
The most noticeable sign is swollen lymph nodes, typically in the neck, armpits, or groin. The swelling is often painless, which can delay people from seeking evaluation. Beyond the visible lumps, DLBCL can cause what oncologists call “B-symptoms”:
- Unexplained fevers that come and go without an obvious infection
- Drenching night sweats severe enough to soak through clothing or bedsheets
- Unintentional weight loss of more than 10% of body weight over six months
Persistent fatigue, chills, and shortness of breath are also common. When the lymphoma develops outside the lymph nodes, symptoms depend on the organ involved. A stomach lymphoma might cause pain or nausea, while one in the chest could lead to coughing or difficulty breathing.
How DLBCL Is Diagnosed
A biopsy of the swollen lymph node or affected tissue is essential. Pathologists examine the sample under a microscope and run a panel of staining tests to identify specific proteins on the surface of the cells. DLBCL cells are characteristically large, appear disorganized (diffuse rather than clustered in follicles), and test positive for a protein called CD20, which confirms they are B-cells. The growth rate is typically very high, with more than 80% of the tumor cells actively dividing.
Additional staining helps classify the lymphoma into molecular subtypes. Using what’s known as the Hans algorithm, pathologists test for three markers to determine whether the cancer originated from germinal center B-cells (GCB subtype) or activated B-cells (ABC subtype). This distinction matters because the ABC subtype tends to have a worse prognosis with standard treatment than the GCB subtype.
Staging
Once diagnosed, imaging scans (typically PET-CT) and sometimes a bone marrow biopsy are used to determine how far the lymphoma has spread. DLBCL follows the Ann Arbor staging system:
- Stage I: Found in a single lymph node region or one organ
- Stage II: Found in two or more lymph node regions on the same side of the diaphragm
- Stage III: Found in lymph node regions on both sides of the diaphragm
- Stage IV: Spread widely into organs outside the lymph system, such as the liver, bone marrow, or lungs
About 37% of cases are already stage IV at diagnosis, largely because the disease can grow quickly and early symptoms are easy to overlook. Stage at diagnosis is one of the strongest predictors of outcome.
Treatment
The standard first-line treatment for DLBCL is a combination regimen called R-CHOP, which pairs a targeted antibody therapy (rituximab) with three chemotherapy drugs and a steroid. Rituximab works by locking onto the CD20 protein on the surface of the cancerous B-cells, flagging them for destruction by the immune system. The chemotherapy drugs attack rapidly dividing cells, and the steroid reduces inflammation and enhances the effectiveness of the other drugs.
R-CHOP is typically given in cycles, with each cycle spaced about three weeks apart to give the body time to recover. The total number of cycles depends on the stage and how the lymphoma responds. Many patients receive six cycles. Side effects during treatment commonly include fatigue, nausea, hair loss, and increased vulnerability to infections due to lowered white blood cell counts.
For patients whose lymphoma comes back after initial treatment or doesn’t respond to it, options have expanded significantly. CAR-T cell therapy, in which a patient’s own immune cells are collected, genetically reprogrammed to recognize the lymphoma, and infused back into the body, is now available for patients who have relapsed after two or more lines of treatment.
Survival Rates by Stage
Five-year relative survival rates for DLBCL, based on data from 2015 to 2021, show that earlier detection correlates strongly with better outcomes:
- Stage I: 80.0% (about 20% of cases are caught at this stage)
- Stage II: 75.8%
- Stage III: 67.3%
- Stage IV: 55.8%
These numbers reflect all patients across age groups and subtypes, so individual outcomes vary. The molecular subtype matters too. Patients with the GCB subtype generally fare better with standard treatment than those with the ABC subtype. Younger age, fewer symptoms at diagnosis, and good overall health before treatment also improve the outlook. Because DLBCL is aggressive but treatment-responsive, a significant portion of patients, even those diagnosed at advanced stages, achieve long-term remission.